MARKETS
Analyst Actions

Cantor Fitzgerald Maintains Neutral on Pfizer, Raises Price Target to $28

Oct 8, 2026 · 06:45 AM ET· updated 9h ago

Cantor Fitzgerald analyst Carter Gould maintains Pfizer (NYSE:PFE) with a Neutral and raises the price target from $27 to $28.

Share
Why It Matters

An expert analyst raised their price guess for Pfizer from $27 to $28. They still think the stock is neither especially good nor bad to own.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.